Form 4: Provectus Biopharmaceuticals CEO Edward Pershing Reports Conversion of Convertible Note into Preferred Stock

CEO Edward Pershing reports the conversion of a convertible note into Series D-1 Preferred Stock and subsequent conversion of preferred stock into common stock.

Summary

• On May 12, 2024, Edward Pershing, CEO of Provectus Biopharmaceuticals, reported transactions involving derivative securities.
• An 8% unsecured convertible promissory note was converted into 75,503 shares of Series D-1 Convertible Preferred Stock at a price of $2.862.
• These 75,503 shares of Series D-1 Convertible Preferred Stock were then converted into 755,030 shares of common stock.
• Following these transactions, Pershing directly owns 1,254,207 shares of common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of transactions. It doesn't inherently indicate positive or negative sentiment, but rather provides information about changes in ownership.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in Edward Pershing's ownership stake in Provectus Biopharmaceuticals.

Stakeholder Impact

• The conversion of preferred stock to common stock may dilute existing shareholders' ownership.

Key Dates